ERBB2 is a transmembrane tyrosine kinase receptor (TKR) member of the epidermal growth factor receptor (EGFR) family. In the context of ERBB2 amplification and resulting overexpression of ERBB2, heterodimerization of ERBB2 with other EGFR members or homodimerization is promoted and ERBB2 autophosphorylation of tyrosine residues in the cytoplasmic domain occurs, leading to a cascade of events promoting tumor formation. It has been argued that homodimeric ERBB2 receptors are less tumorigenic than the corresponding heterodimeric pairs and that heterodimers containing ERBB2 have more transforming capacity. Furthermore, HER2/EGFR and HER2/ERBB3 heterodimers impact signaling differentially. HER2 gene abnormalities have been found in breast cancer, nested cancer, gastrointestinal cancer and lung cancer, and HER2 mutations account for about 2% to 4% of NSCLC cases.The EGFR family of inhibitors Afatinib (Gilotrif) and the antibody conjugate drug (ADC) Enhertu are used to treat ERBB2 positivity.ERBB3 (also known as HER3, human epidermal growth factor receptor 3) is a member of epidermal growth factor receptor family (EGFR). Because ERBB3 lacks intrinsic kinase activity of its own, it is unable to transmit signals to the cell through protein phosphorylation. ERBB3 binds to the ligand Neurogulin (NRG-1/-2), also known as heregulin (HRG-1/-2). Ligand binding induces a conformational change in ERBB3, thereby achieving dimerization, phosphorylation, and activation of signaling pathways. ERBB3 is expressed in the gastrointestinal tract, reproductive system, skin, nervous system, urinary tract, and endocrine system in normal adults. Indeed, ERBB3 itself is regulated to varying degrees, with its ubiquitination and proteasomal degradation regulated by 2 ubiquitin ligases, NEDD4 and NRDP1. ERBB3 overexpression was observed in breast cancer, lung cancer, colorectal cancer, gastric cancer, head and neck squamous cell carcinoma, ovarian cancer, melanoma, prostate cancer and bladder cancer. The ERBB3 target drugs Patritumab Deruxtecan and Izalontamab are in phase III clinical trials.